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RX Base 3 mos 1yr Base 3 mos 1yr Base 3 mas 1yr
AT 12 +9* +9 17 +7# +15 27.1 +0.6 -0.1
CP 23 -8* -4 33 -7 -4 281 0 +0.2
CL 16 +3 0 22 +5 +2 28.4 +0.3 -0.4
DT 18 +5 +8 29 +6 +16@ 300 -0.9 -0.5
HZ 26 -5 -9 41 -8# -9@ 29.4 -0.5 -1.5
PZ 23 +1 -4 33 -1 +3 28.4 -0.1 +07
PL 16 +5 25 +7 28.3 +0.4 +1.1
* AT v CP 3 mos, # HZ v AT 3 mos, @ HZ v DZ 1 yr (p < 0.05)
Thus, HZ caused a decrease in LVH prevalence, while AT and DT caused an
increase. These changes are concordant with echo observations, where HZ
was the only drug to significantly reduce LV mass for equal levels of systolic
BP reduction.
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Incidence of and Factors Associated with Abrupt
Closure in Patients Undergoing Elective, New Device
Angioplasty in Native Coronary Arteries
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The sole independent predictor for out-of-Iab only abrupt closure was dis-
section (Odds Ratio = 3.11, p < 0.005). We conclude that; (1) The incidence
of abrupt closure (both in- and out-of-Iab) was 3.9% in patients undergoing
elective new device angioplasty, with nearly equal distribution of in- and out-
of-lab occurrences: (2) Unstable angina. lesion length ~ 10 mm, and angula-
tion ~45° predicted either in- or out-of-Iab abrupt closure, whereas dissection
was the sole significant predictor of out-of-Iab only abrupt closure: and (3)
both lesion-related (thrombus-containing lesions for extraction atherectomy)
and device-related factors (stents with subacute thrombosis) added to the
acceptable rates of abrupt closure with these new devices for lesions unfa-
vorable for conventional angioplasty.
c.1. = confidence interval
To determine the incidence and predictors of abrupt closure (TIMI flow = 0
or 1) in patients undergoing new device angioplasty (NDA). we studied the
hospital records and qualitative morphologic and quantitative angiographic
methods of 1,983 patients with unfavorable lesion morphologies treated
electively in native coronary arteries with intracoronary stents (N = 96), ex-
traction atherectomy (TEC; N = 27). directional atherectomy (N = 563), ro-
tational atherectomy (N = 775), or laser (N = 522). The overall incidence
of abrupt closure was 3.9% (78/1983), with 2.1 % (42/78) occurring during
the procedure and 1.8% (36/78) occurring out-of-Iab (1 patient with both in-
and out-of-Iab abrupt closure). Among NDA. TEC (14.8%) and stents (8.3%)
had relatively higher frequencies of abrupt closure compared to other NDAs
(mean of 3.5%). Multivariate analysis of demographic and lesion characteris-
tics revealed the following predictors associated with either in-lab or out-of-
lab abrupt closure:
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1720-21 Predictors of Acute Complications After
Percutaneous Coronary Revascularization with New
Devices
Peter A. McCullough, William W. O'Neill, Melissa May, Anne Lichtenberg,
Michelle Strzelecki, Cindy L. Grines, Robert D. Safian. William Beaumont Hospital,
Royal Oak, MI
Studies of conventional balloon angioplasty (PTCA) have identified female
gender, age, unstable angina. prior coronary bypass surgery. diabetes, le-
sion thrombus, and dissection as predictors of acute complications, but pre-
dictors of the risks of new device interventions are unknown. New devices
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Days Control Ouinapril Hydralazine
LVMI aM ,IlM LVMI aM ,IlM LVMI aM ,IlM
0 2.66 1.0 1.0 2.66 1.0 10 266 1.0 1.0
2 2.61 12 1.1 255 15 0.8 2.60 1.5 1.1
4 2.62 0.8 0.8 2.59 2.3* OS 2.64 1.6 0.6
7 2.74 0.9 0.9 2.37* 1.9* 07 2.48 2.1* 0.6
10 2.74 0.9 1.3 2.39* 2.5* 0.5* 2.81 1.1' 0.5*
21 270 1.2 1.2 2.35* 2.5* 0.5* 2.58 1.9* 0.4*
Group N MAP MAF SAR + DP/DT LVMI V1 V2 V3
Placebo 17 151* 105* 1.57* 16246* 2.98 ns 32* 23 45*
Hydralazine 18 104 164 067 8562 280 68 15 17
Enalapril 13 94 144 0.68 8633 2.19# 80 11 9
Control 11 85 179 0.49 13022 255 60 15 25
Chronic Hydralazine or Enalapril Normalize
Myosin Isoforms in the Spontaneously
Hypertensive Rat, but Only Enalapril Normalizes
Left Ventricular Mass
Garrie J. Haas, Margaret Ginn Pease, Melinda Hunnicutt, Mary E. Allon, A.
John Merola, Robert J. Cody. The Ohio State University. Columbus, Ohio
These data show that reduction in hemodynamic load induced a change in
myosin isoforms to adult pattern whereas only Q reduced LVMI, suggesting
that LVH reversal may not be dependent solely on hemodynamic load.
Increased V3 myosin isoform is seen in left ventricular (LV) hypertrophy (H),
but reversion to V1 with chronic afterload reduction and LVH regression is
not well defined. We randomized SHR at 3-4 months to oral hydralazine (25
mglkg), enalapril (40 mglkg), or placebo. Age matched Wistar Kyoto rats were
controls. Group average systolic blood pressure (mmHg) at baseline was
207 (Plac), 223 (Hydrl), 225 (Enal), and 156 (Cntrl). Rats were studied after
3 months of treatment. Echocardiographic LVmass (LVM) was from the cu-
bic function: LVM (mg) = 1.04[(EDD + PWT + IVS)3 - EDD3]. corrected for
body weight (LVMI), since echocardiography permits better identification of
differing patterns of hypertrophy. Terminal hemodynamics were volumetric
aortic flow (mean: MAF, mllmin) and Millar aortic pressure (mean: MAP). Sys-
temic arterial resistance (SAR) and LV contractility (+dp/dt) was derived from
digitized waveforms. Following termination, LV was harvested and frozen at
-8000 C, and myosin isoforms were determined bygel electrophoresis, with
expression of V1, V2, V3 isoforms as % total. Analysis of variance was per-
formed and group mean values are given below:
LVMI-LV mass index. *p < 0.05, compared with day 0 (same group) or control
*p <. 05, placebo vs Hydrl. and vs Enal. # p < 0.05 placebo vs Enal
Thus, myosin isoform expression reverted to an adult pattern, in response
to long term afterload reduction. Changes in myosin transcriptional patterns
however, require additional assessment. Eccentric hypertrophy accounted
for persistent LVMI following hydralazine, whereas greater LVMI reduction
occurred with ACE inhibition. This suggests that factors other than afterload
reduction contribute to LVMI regression with ACE inhibition.
Both ECG and echo LVH are markers of increased risk, but there is much
less information on interdrug differences in ECG LVH regression. Therefore,
changes in ECG LVH prevalence were examined after 3 mas titration phase
and a 1 yr maintenance phase of randomized double-blind treatment with
atenolol (AT), captopril (CP). clonidine (CL). diltiazem (DT). hydrochloroth-
iazide (HZ), prazosin (PZ) or placebo (PL) in 570 men with mild-moderate hy-
pertension. The prevalence of Sokolow-Lyon (SL) and Minnesota code (MC)
criteria were evaluated, as well as precordial voltage (Svl + Rv5). Percent
changes from baseline were:
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